PNTG Quote, Financials, Valuation and Earnings

Ensign Group has a net margin of 3.71% compared to Pennant Group's net margin of 6.84%. Pennant Group's return on equity of 10.97% beat Ensign Group's return on equity of 17.64%.

Pennant Group has a consensus price target of $33.60, signalling upside risk potential of 15.5%. On the other hand Ensign Group has an analysts' consensus of $165.17 which suggests that it could grow by 7.55%. Given that Pennant Group has higher upside potential than Ensign Group, analysts believe Pennant Group is more attractive than Ensign Group.

Pennant Group has a beta of 1.515, which suggesting that the stock is 51.458% more volatile than S&P 500. In comparison Ensign Group has a beta of 1.032, suggesting its more volatile than the S&P 500 by 3.167%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensign Group offers a yield of 0.16% to investors and pays a quarterly dividend of $0.06 per share. Pennant Group pays -- of its earnings as a dividend. Ensign Group pays out 4.59% of its earnings as a dividend. Ensign Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pennant Group quarterly revenues are $209.8M, which are smaller than Ensign Group quarterly revenues of $1.2B. Pennant Group's net income of $7.8M is lower than Ensign Group's net income of $80.3M. Notably, Pennant Group's price-to-earnings ratio is 38.28x while Ensign Group's PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.29x versus 2.03x for Ensign Group. Usually stocks with elevated PS ratios are considered overvalued.

Guardian Pharmacy Services has a net margin of 3.71% compared to Pennant Group's net margin of 2.87%. Pennant Group's return on equity of 10.97% beat Guardian Pharmacy Services's return on equity of -71.46%.

Pennant Group has a consensus price target of $33.60, signalling upside risk potential of 15.5%. On the other hand Guardian Pharmacy Services has an analysts' consensus of $27.33 which suggests that it could grow by 32.69%. Given that Guardian Pharmacy Services has higher upside potential than Pennant Group, analysts believe Guardian Pharmacy Services is more attractive than Pennant Group.

Pennant Group has a beta of 1.515, which suggesting that the stock is 51.458% more volatile than S&P 500. In comparison Guardian Pharmacy Services has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardian Pharmacy Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. Guardian Pharmacy Services pays out -40.96% of its earnings as a dividend.

Pennant Group quarterly revenues are $209.8M, which are smaller than Guardian Pharmacy Services quarterly revenues of $329.3M. Pennant Group's net income of $7.8M is lower than Guardian Pharmacy Services's net income of $9.4M. Notably, Pennant Group's price-to-earnings ratio is 38.28x while Guardian Pharmacy Services's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.29x versus 1.00x for Guardian Pharmacy Services. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of 3.71% compared to Pennant Group's net margin of 0.21%. Pennant Group's return on equity of 10.97% beat LifeStance Health Group's return on equity of -2.48%.

Pennant Group has a consensus price target of $33.60, signalling upside risk potential of 15.5%. On the other hand LifeStance Health Group has an analysts' consensus of $8.86 which suggests that it could grow by 74.35%. Given that LifeStance Health Group has higher upside potential than Pennant Group, analysts believe LifeStance Health Group is more attractive than Pennant Group.

Pennant Group has a beta of 1.515, which suggesting that the stock is 51.458% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

Pennant Group quarterly revenues are $209.8M, which are smaller than LifeStance Health Group quarterly revenues of $333M. Pennant Group's net income of $7.8M is higher than LifeStance Health Group's net income of $709K. Notably, Pennant Group's price-to-earnings ratio is 38.28x while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.29x versus 1.51x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group has a net margin of 3.71% compared to Pennant Group's net margin of -1.11%. Pennant Group's return on equity of 10.97% beat PACS Group's return on equity of --.

Pennant Group has a consensus price target of $33.60, signalling upside risk potential of 15.5%. On the other hand PACS Group has an analysts' consensus of $30.50 which suggests that it could grow by 141.11%. Given that PACS Group has higher upside potential than Pennant Group, analysts believe PACS Group is more attractive than Pennant Group.

Pennant Group has a beta of 1.515, which suggesting that the stock is 51.458% more volatile than S&P 500. In comparison PACS Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. PACS Group pays out 71.23% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pennant Group quarterly revenues are $209.8M, which are smaller than PACS Group quarterly revenues of $981.8M. Pennant Group's net income of $7.8M is higher than PACS Group's net income of -$10.9M. Notably, Pennant Group's price-to-earnings ratio is 38.28x while PACS Group's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.29x versus 0.56x for PACS Group. Usually stocks with elevated PS ratios are considered overvalued.